较高羟氯喹血药浓度与系统性红斑狼疮血栓风险降低相关
该纵向队列研究纳入739例系统性红斑狼疮(SLE)患者,系列定量EDTA全血羟氯喹(HCQ)浓度,分析其与血栓事件的关联。结果显示血栓发生率为5.1%,发生血栓者平均HCQ血药浓度较低;最新HCQ血药浓度每增加200 ng/ml,血栓发生率降低13%。平均HCQ血药浓度≥1,068 ng/ml者较<648 ng/ml者血栓事件减少69%,校正混杂因素后仍显著。
要点
- SLE患者中较低HCQ血药浓度与血栓事件相关。
- 最新HCQ血药浓度每增加200 ng/ml,血栓发生率降低13%。
- 平均HCQ血药浓度≥1,068 ng/ml者血栓风险显著低于<648 ng/ml者。
核心结论
- 低HCQ血药浓度与SLE患者血栓事件相关,纵向监测HCQ血药浓度可能有助于个体化给药。
研究设计与样本
- 纵向SLE队列研究,纳入739例SLE患者,系列定量EDTA全血HCQ浓度。
主要发现
- 739例SLE患者中38例(5.1%)发生血栓。
- 发生血栓者平均±SD HCQ血药浓度为720±489 ng/ml,未发生血栓者为935±580 ng/ml(P=0.025)。
- 最新HCQ血药浓度每增加200 ng/ml,血栓发生率降低13%(RR 0.87 [95% CI 0.78-0.98],P=0.025)。
- 平均HCQ血药浓度每增加200 ng/ml,血栓发生率降低13%(RR 0.87 [95% CI 0.76-1.00],P=0.056)。
- 平均HCQ血药浓度≥1,068 ng/ml者较<648 ng/ml者血栓事件减少69%(RR 0.31 [95% CI 0.11-0.86],P=0.024),校正混杂因素后仍显著(RR 0.34 [95% CI 0.12-0.94],P=0.037)。
临床怎么用
- 对SLE患者可考虑纵向监测HCQ血药浓度以评估血栓风险并指导个体化给药。
- 经验性减少HCQ剂量可能削弱或消除该高风险人群中HCQ的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus (SLE) and may be protective against thrombosis in SLE. Optimal weight-based dosing of HCQ is unknown. This study was undertaken to examine the usefulness of HCQ blood monitoring in predicting thrombosis risk in a longitudinal SLE cohort. METHODS: HCQ levels were serially quantified from EDTA whole blood by liquid chromatography-tandem mass spectrometry. The mean HCQ blood levels calculated prior to thrombosis or until the last visit were compared using t-tests between patients with and those without thrombosis. Pooled logistic regression was used to analyze the association between rates of thrombosis and HCQ blood level. Rate ratios (RRs) and 95% confidence intervals (95% CIs) were calculated. RESULTS: In 739 patients with SLE, thrombosis occurred in 38 patients (5.1%). The mean ± SD HCQ blood level was lower in patients who developed thrombosis versus those who did not develop thrombosis (720 ± 489 ng/ml versus 935 ± 580 ng/ml; P = 0.025). Thrombosis rates were reduced by 13% for every 200-ng/ml increase in the most recent HCQ blood level (RR 0.87 [95% CI 0.78-0.98], P = 0.025) and by 13% for mean HCQ blood level (RR 0.87 [95% CI 0.76-1.00], P = 0.056). Thrombotic events were reduced by 69% in patients with mean HCQ blood levels ≥1,068 ng/ml versus those with levels <648 ng/ml (RR 0.31 [95% CI 0.11-0.86], P = 0.024). This remained significant after adjustment for confounders (RR 0.34 [95% CI 0.12-0.94], P = 0.037). CONCLUSION: Low HCQ blood levels are associated with thrombotic events in SLE. Longitudinal measurement of HCQ levels may allow for personalized HCQ dosing strategies. Recommendations for empirical dose reduction may reduce or eliminate the benefits of HCQ in this high-risk population.
引用
- Petri M, Konig MF, Li J, et al. Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2021. PMID: 33403833. doi:10.1002/art.41621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。